Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia
Status:
Active, not recruiting
Trial end date:
2021-11-17
Target enrollment:
Participant gender:
Summary
We aim to assess the benefits and harms of higher (12 mg) vs lower doses (6 mg) of
dexamethasone on patient-centered outcomes in patients with COVID-19 and severe hypoxia.
Phase:
Phase 3
Details
Lead Sponsor:
Scandinavian Critical Care Trials Group
Collaborators:
Aalborg University Hospital Aarhus University Hospital Centre for Research in Intensive Care (CRIC) Copenhagen Trial Unit, Center for Clinical Intervention Research Rigshospitalet, Denmark The George Institute for Global Health, Australia